Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
54868-5738-01 54868-5738 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec 29, 2006 In Use
65862-0390-10 65862-0390 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 12, 2010 In Use
57237-0075-30 57237-0075 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 31, 2007 In Use
58118-0240-04 58118-0240 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 2, 2007 Jun 26, 2017 No Longer Used
36000-0012-25 36000-0012 Ondansetron Hydrochloride Ondansetron Hydrochloride 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Mar 13, 2013 No Longer Used
69189-0679-01 69189-0679 Dolasetron mesylate Anzemet 100.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jul 26, 2016 May 24, 2017 No Longer Used
63187-0526-12 63187-0526 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 20, 2023 In Use
00078-1196-20 00078-1196 Asciminib SCEMBLIX 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Apr 18, 2024 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1098-94 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct 29, 2021 In Use
68727-0712-01 68727-0712 Lurbinectedin ZEPZELCA 0.5 mg/mL Chemotherapy Alkylating Agent Adduct Forming Agent Intravenous Jun 15, 2020 In Use
00015-3080-60 00015-3080 Mitotane Lysodren 500.0 mg/1 Chemotherapy Miscellaneous Agent Adrenal Suppressant Oral Jun 1, 2009 Mar 31, 2021 No Longer Used
00310-9501-96 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 23, 2024 In Use
00310-9501-02 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
00310-9500-01 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9501-01 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Nov 16, 2023 In Use
00310-9500-02 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
00310-9501-95 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Feb 1, 2024 Oct 28, 2024 In Use
50242-0130-01 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Dec 11, 2015 In Use
00069-8141-20 00069-8141 Crizotinib Xalkori 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Aug 26, 2011 In Use
00078-0694-84 00078-0694 ceritinib ZYKADIA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Mar 18, 2019 In Use
00069-8140-20 00069-8140 Crizotinib Xalkori 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Aug 26, 2011 In Use

Found 11765 results — Export these results